In conclusion, this study provides evidence that SH3TC2 gene replacement using a Schwann cell targeted viral vector can provide a therapeutic benefit in a model of CMT4C demyelinating neuropathy, leading to partial rescue of functional, electrophysiological and morphological abnormalities. Here, SH3TC2 is linked to Charcot-Marie-Tooth disease type 4C.